2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Gene Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1155 Maternal cannabinoid exposure leads to modulation in placental epigenome signatures and generational neurodegeneration in sickle cell mice

Donovan Alexander Argueta, PhD, Reina Lomeli2, Carolina Mireles, BS3, Graham Velasco4, Raghda Fouda5, Kalpna Gupta, PhD6
1 University of California Irvine, Irvine, California, United States
2 University of California Irvine, Irvine, California, United States
3 University of California Irvine, Irvine, California, United States
4 VA Long Beach Healthcare System, Long Beach, California, United States
5 Stanford University, Stanford, California, United States
6 University of California Irvine, Irvine, California, United States

More than 5% of individuals report cannabis use during pregnancy. Cannabinoid (CB) use is higher in persons with sickle cell disease (SCD) vs other conditions. CB use increases during pregnancy because the lifesaving hydroxyurea (HU) for SCD is discontinued because of its teratogenic effect, but the use of CBs to control pain may have devastating consequences. A single in utero exposure to synthetic CB (CP55,940) or Δ9-tetrahydrocannabinol (THC) produced developmental changes in the offspring of C57BL/6 mice (Fish et al., Sci. Rep. 2019). Simulating the situation in pregnancy in SCD, we examined the role for HU termination prior to pregnancy and CB exposure during pregnancy on the placental epigenome, offspring brain health, and development of hyperalgesia using humanized transgenic BERK, homozygous (SS) and hemizygous (AS) expressing human sickle hemoglobin (Hb), and control (AA) mice expressing normal human HbA.  

AS females were bred with SS males, because SS females breed poorly. Females received HU (i.p., 50 mg/kg/day), CP55,940 (CP; i.p., 0.3 mg/kg/day), or vehicle (Veh; 2% DMSO in sterile saline) for 2-weeks prior to mating. During gestation until birth, Veh and CP treatment continued, while HU was discontinued and replaced with Veh or CP (HU+CP) for the remainder of the exposure. Placenta were collected at embryonic day 18 for histology and whole methylome analysis. Offspring were evaluated for hyperalgesia at 2- and 3-months of age; brains were collected at 3 mo. for analysis of regions related to pain and cognitive function.

H&E staining of the placenta revealed a dysregulation of junctional zone (JZ) thickness as follows; Abnormal thinning with CP exposure (50%, P<.05 vs Veh), suggesting reduced cellularity and consequently impaired endocrine function, whereas HU caused significant JZ thickening (placentomegaly, 52%, P<.05 vs Veh), which has been associated with pregnancy complications,  and impaired placental barrier function; both can contribute to impaired nutritional and oxygen supply leading to fetal distress and impaired development. HU+CP exposure resulted in no net change in JZ thickness vs Veh. Placental whole methylome revealed that genes regulating placental function and offspring development were significantly impacted. Gene ontology (GO) enrichment analysis indicated disruption of several pathways (represented as q=adjusted P-values): Vs Veh, CP caused disruption to axonogenesis (q<.001), dendrite development (q<.001), synapse organization (q<.01), and postsynapse organization (q<.01); meanwhile, HU caused disruption to cell-cell adhesion (q<.001), cell junction assembly (q<.001), and regulation of synapse structure and activity (q<.001); each of these pathways was further disrupted by HU+CP compared to either alone. Epigenetic modulation (epigenetic memory) induced by CB and/or HU treatments in the placenta may impair lifelong offspring development. SS mice typically develop chronic mechanical, cold and musculoskeletal hyperalgesia at ~3 mo. Maternal exposure to CP and HU+CP increased musculoskeletal hyperalgesia in male and female SS offspring at 2 mo. (P<.001 vs Veh). CP and HU+CP exacerbated mechanical and cold hyperalgesia in 3 mo. male and female SS mice (P<.05 vs Veh/Hu). No differences in hyperalgesia were observed in AA offspring. In 3 mo. offspring, anterior cingulate cortex and somatosensory cortex, which control peripheral inputs related to itch and pain, revealed a significant increase in pyknotic neurons with CP as well as with HU+CP exposure (P<.05 vs Veh). CP increased the number of pyknotic neurons in the CA1 region of the hippocampus (P<.05), however, all exposures contributed to significant pyknosis in the dentate gyrus (P<.05 vs Veh); these hippocampal regions contribute to emotional aspects of chronic pain and response to ischemic injury, suggestive of earlier manifestation of pain and possibly increased pain intensity during vasoocclusive crises. These early developmental alterations may also lead to exacerbated neurodegeneration with aging and spontaneous insults such as vasooclusion. Our data evinces that perinatal CB exposure confers risk of developmental defects, and early onset/worsening of hyperalgesia to offspring. Thus, our maternal and fetal multi-system data suggests that persons with SCD may be at an increased risk of long-term comorbidities due to maternal exposure to CBs, which needs to be critically evaluated clinically in SCD.

Donovan Alexander Argueta, PhD: No relevant conflicts of interest to declare.